York PhD in Metal-Based Antibiotic Discovery: Sustainable Automated Synthesis and Target-Based Screening

York PhD in Metal-Based Antibiotic Discovery: Sustainable Automated Synthesis and Target-Based Screening

Executive Verdict

Can metal-complex chemistry, automation and data analysis provide useful evidence for antimicrobial discovery while reducing material use? P10 brings these disciplines together, with the difficult task of keeping chemical characterisation, target-level signals, wider biological effects and model predictions in their proper evidential roles. It is a strong platform for a chemistry-led applicant, subject to clear supervision and written funding terms.

The 2027/28 EPSRC Chemical Synthesis for a Healthy Planet CDT information identifies this as a four-year project. The official project page names the University of York as the host, Dr Angelo Frei as supervisor and the INEOS Oxford Institute for Antimicrobial Research (IOI) as industrial partner. The project is scientifically ambitious but coherent: it links automated metal-complex discovery, target-informed biological assessment and human-guided machine learning in a four-year doctorate.

This is not a speculative platform assembled only for recruitment. Frei's official York profile directly covers metal complexes, antibiotics, machine learning and automation. His recent work includes a peer-reviewed ML-guided metalloantibiotic study and a York-led high-throughput metal-complex discovery paper. York also has a visible digital-chemistry theme and relevant analytical infrastructure. That makes the supervisor–project fit unusually strong.

For a Chinese applicant, the critical distinction is between permission to apply and a financially usable offer. International applicants are allowed to compete, but the public documents do not conclusively prove that P10 automatically covers the overseas tuition-fee difference for all four years. The programme calls the doctorate fully funded, while York's detailed CSHP funding page specifies tuition at the UK rate. UKRI's training-grant guidance says that an overseas-fee difference may be charged, waived or paid from another non-UKRI source. York separately says that it covers the difference for recipients of certain UKRI doctoral focal and landscape awards, but the general wording does not explicitly identify P10. The safe decision rule is therefore simple: do not accept an offer until the funding letter names the payer and confirms full international tuition coverage, including annual increases, for all four years.

The project is best suited to an applicant with a strong base in inorganic, coordination, medicinal or synthetic chemistry who wants to become fluent in automation and scientific data analysis. It is less suitable for someone seeking a mostly computational PhD, a predictable low-risk endpoint or a single-site, single-supervisor environment.

Recorded Project and Application Timing

The 2027/28 programme research-project page lists P10. The official description confirms:

• host institution: University of York;
• primary named supervisor: Dr Angelo Frei;
• industrial partner: INEOS Oxford Institute for Antimicrobial Research;
• broad training interface: chemistry, microbiology, automation and data-guided molecular design;
• programme length: four years, including an initial cohort-training period across Oxford and York. The CSHP programme information advertises up to sixteen four-year studentships across the annual intake, of which three or four are normally based at York; these programme-wide figures do not establish a place for P10. The How to Apply page gives the next deadline as Friday 13 November 2026 at 12 noon (timezone not stated) and states that candidates apply directly to the host institution of their preferred project.

The project advertisement says applications may continue after the first round, but projects may be filled from that round. A serious P10 applicant should therefore treat 13 November at 12 noon (timezone not stated) as the operative deadline rather than rely on later consideration.

The programme-wide page and York-host instructions are not identical in every document detail. The York Chemistry application should be treated as controlling for a York-hosted project. Before submitting, confirm the current portal requirements for the personal statement, the ranked project choices, transcript, CV, references and York's equality-data form. Do not assume that Oxford-host reference requirements apply unchanged to York.

Doctoral work and evidence boundaries

The saved call describes a linked sequence: sustainable metal-complex synthesis and automated exploration at York; target-informed biological assessment with IOI; and human-guided machine learning to prioritise focused follow-up libraries. It identifies bacterial cell-wall targets, including transpeptidases and related enzymes. Promising candidates are to be resynthesised and characterised before evidence moves from target-level assessment to whole-cell activity, including clinical isolates and isogenic strains. These are distinct evidence levels; the project does not guarantee an effective antibiotic or clinical outcome. Individual responsibilities, detailed design and approved access remain to be agreed with the supervisors.

School, Programme and Location Signal

York Chemistry has a strong current UK subject signal. Its department overview reports 8th in the 2027 Complete University Guide, 4th in the 2026 Times and Sunday Times Good University Guide and 9th in the UK for research in the department's presentation of the latest REF results. Rankings are not evidence that an individual PhD will succeed, but they support the conclusion that P10 sits in an established research department rather than an isolated laboratory.

The CDT structure adds a more relevant advantage. The programme describes a four-month initial training period at both Oxford and York, followed by the main project at the host university. Its network includes more than forty academics, ten industrial partners and ten SMEs. For P10, this structure can help bridge inorganic chemistry, automation, machine learning and antimicrobial biology. It also creates obligations: mandatory training, cross-site travel and partner coordination can consume meaningful time. Applicants should ask how frequently travel continues after the initial block and which costs are paid outside the stipend.

The project will primarily be based in York, United Kingdom. Oxford contributes through IOI, but the public page does not describe P10 as an Oxford registration or guarantee a fixed Oxford placement. That distinction matters for daily supervision, travel and access to partner facilities.

Supervisor and Research-Environment Assessment

Supervisor fit

Angelo Frei's York profile identifies him as a Senior Lecturer in Inorganic Chemistry and lists metal complexes, antibiotics, machine learning, automation and medicinal chemistry as core interests. The profile also shows a research path spanning medicinal metal complexes and antimicrobial discovery. York's institutional research database records current projects in ML-guided exploration of transition-metal chemical space, recent peer-reviewed outputs and deposited datasets. The match is direct and current.

The main concern is not topic mismatch but supervisory breadth. The official P10 page names only Frei as an academic supervisor, even though the project also depends on target biology, microbiology, data science and cross-site work. IOI is listed as industrial partner, but no named IOI co-supervisor appears. Applicants should ask who will provide routine biological and ML oversight, who has authority to set priorities when the chemistry and biological data conflict, and how often the York and Oxford team will meet.

Recent important publications

• Metals to combat antimicrobial resistance, Nature Reviews Chemistry (2023). This Frei-led review is the field-level foundation. It explains why metal complexes provide chemical and biological diversity beyond conventional organic scaffolds and why AMR is a compelling use case. Its value for applicants is conceptual: it also makes clear that metal-based medicines bring non-trivial questions around stability, speciation, selectivity, toxicity, mechanism and translation.
• Using Machine Learning to Predict the Antibacterial Activity of Ruthenium Complexes, Angewandte Chemie International Edition (2024). This is the closest direct precedent for P10's data-guided design loop. The authors reported that models trained on a specialised coordination-complex dataset enriched the hit rate in a follow-up set. The important limitation is external validity: a small, chemistry-specific dataset does not prove that a model will transfer to new metals, targets, assay formats or an evolving P10 dataset.
• High-throughput triazole-based combinatorial click chemistry for the synthesis and identification of functional metal complexes, Nature Communications (2025). This York-led paper provides direct evidence of an automated workflow that generated and evaluated hundreds of metal complexes. It is strong execution evidence for the P10 platform. It also reinforces a key diligence point: signals from high-throughput libraries require rigorous confirmation with fully characterised material before they are treated as reliable leads. York's September 2026 robot-assisted metalloantibiotic discovery report further shows that the platform remains active. Institutional news is not a substitute for the peer-reviewed papers, but it supports current team continuity and equipment use.

Automation, computation and analytical resources

York's Digital Chemistry theme covers machine learning, data-rich discovery, laboratory robotics, chemical informatics, digital analytical science and human–AI teaming. Frei is listed as theme lead, and the page names robotics and high-performance-computing resources. This is a better signal than a generic claim that the department “uses AI.”

The Green Chemistry Centre of Excellence facilities page documents a substantial analytical environment, specialist research equipment and an industrial engagement facility. These sources make the infrastructure credible at institutional level. They do not answer the operational questions that matter to a PhD student: which robot and analytical systems are reserved for P10, expected queue times, technician support, maintenance contingency, data storage, compute quotas, software licensing and whether the project budget covers repeated confirmation work.

The distinction between platform availability and guaranteed access should be resolved before accepting an offer. A strong department can still have bottlenecks if several projects depend on the same automation or analytical systems.

INEOS Oxford Institute Collaboration

Oxford's official account of IOI's creation confirms a major interdisciplinary AMR institute linking Chemistry and Biology. The Oxford AMR Network reports more than 200 researchers working across drug discovery, pathogenesis, diagnostics, surveillance and other AMR areas, with the network hosted and funded by IOI.

This gives P10 access to a credible antimicrobial ecosystem. However, the label “industrial partner” should be interpreted carefully. IOI is an Oxford research institute established through a large INEOS donation; the public evidence does not describe a conventional pharmaceutical-company placement, employment pathway or guaranteed commercial programme. The P10 page also does not name the partner supervisor or specify committed assays, staff time, materials, datasets or facilities.

Applicants should request a concrete partner plan covering:

• the named IOI academic and day-to-day contacts;
• expected periods in Oxford and travel frequency;
• which partner resources are committed rather than merely available in principle;
• how cross-site samples and data are governed;
• ownership of compounds, raw data, curated datasets, models and code;
• confidentiality, publication-review and thesis-embargo rules;
• whether the partner can redirect project priorities and how disputes are resolved. These are normal diligence questions for collaborative doctoral research, not signs that the partnership is weak.

Research Direction and Field Outlook

Scientific opportunity

Metal complexes can provide three-dimensional structures, electronic properties and potential mechanisms that are difficult to access with conventional organic molecules. This creates a differentiated discovery space at a time when the antibiotic pipeline needs genuine innovation. P10 also has a sensible feedback logic: use automation to make exploration tractable, collect structured evidence, and use human-guided modelling to prioritise the next decisions.

The opportunity is strongest if the doctorate treats data quality and uncertainty as central scientific problems. Coordination compounds are not represented as cleanly as conventional small organic molecules, and experimental datasets may be small, imbalanced and collected across changing conditions. A model can appear accurate because of near-duplicate compounds, hidden batch effects or train/test leakage. It can also fail when a new metal, ligand family, target or assay lies outside the training domain. A good P10 thesis should therefore be judged not only by the number of predicted hits but by reproducibility, applicability-domain clarity, calibrated uncertainty and meaningful prospective validation.

Translation risk

The largest scientific risk is the chain from early target-level evidence to robust whole-cell performance and then to a credible preclinical direction. A signal can be lost when preliminary material is remade and characterised. Target engagement does not guarantee cell entry, intracellular availability or selectivity. Metal-containing compounds introduce additional questions around speciation, stability, off-target reactivity and toxicity. Biological systems add uptake, efflux and resistance mechanisms that are not visible in a purified-target assay.

These risks do not make the doctorate unattractive. They make milestone design important. The supervisor should be able to explain which outputs remain publishable if later biological translation fails: for example, a validated automation/data platform, a rigorous negative result about model transfer, a high-quality structure–property dataset or a confirmed target-level chemical series. The public project page does not disclose its stage gates or fallback thesis plan.

Sustainability claims

Miniaturisation and reduced material use can improve discovery efficiency, but they do not automatically prove that the overall workflow is sustainable. A credible assessment should also account for solvent and consumables use, failed or repeated runs, automation energy, analytical burden, metal sourcing and waste handling. Applicants should ask which sustainability metrics the CDT expects and whether environmental performance is evaluated alongside hit rate and scientific novelty.

Field and career outlook

The UK's 2024–2029 AMR action plan prioritises new antimicrobials, evidence generation, research networks and collaboration across academia, industry and the public sector. AMR drug discovery nevertheless has commercial and translational barriers, so policy priority should not be confused with a guaranteed job market for one specific modality.

P10's portable skills are broader than “metal antibiotics.” Potential directions include medicinal or inorganic chemistry, laboratory automation, high-throughput discovery, analytical science, cheminformatics, scientific software/data stewardship, antimicrobial R&D and platform technology. The UK government's life-sciences skills assessment identifies growing demand for hybrid science/data/AI roles, lab automation and responsible governance skills. Those forecasts are directional, not an employment guarantee. The student's value will depend on demonstrable, transferable outputs: reproducible automation, rigorous analytical confirmation, transparent code and data, honest model validation and the ability to communicate across chemistry and biology.

Funding and Financial Feasibility for a Chinese Applicant

Published funding terms and their limits

• The programme accepts international applicants.
• International awards are constrained by UKRI allocation rules; programme material cites an upper limit of 30% of funded places.
• York's scheme page describes a four-year stipend, research costs and tuition at the UK rate.
• UKRI currently lists a minimum stipend of £21,805 from October 2026, but the exact 2027-entry amount has not yet been established by the public P10 documents.
• York lists the 2027/28 full-time international Chemistry PhD fee as £30,950 per year on its international research-fee page, with later-year fees subject to inflation-linked increases.

What remains unresolved

The phrase “fully funded” on the programme home page does not, by itself, resolve the overseas-fee difference. The detailed York scheme page's UK-rate wording points in the opposite direction, while programme FAQ material recommends that international applicants consider a scholarship for the fee difference. UKRI rules permit the difference to be waived or funded elsewhere but do not require UKRI to pay it.

York's general doctoral-training page says the university covers the home/international fee difference for international recipients of specified UKRI doctoral focal and landscape awards. That is encouraging, but it does not expressly state that the policy applies to this CDT project and this 2027/28 award. The public evidence is therefore conflicting or incomplete rather than clearly negative.

Before accepting, the applicant should obtain a written answer to all of the following:

1. Does the P10 award cover 100% of international tuition in year one?
2. Who pays every later annual increase through year four?
3. Is any separate scholarship application or ranking needed?
4. Are visa, immigration health surcharge, relocation and cross-site travel covered?
5. What happens financially if completion or examination extends beyond the funded period? An offer that covers the stipend but leaves a substantial fee difference to the student is not a fully funded offer in practical terms.

Living cost signal

York's 2026/27 postgraduate accommodation page lists 51-week university accommodation from £186 per week for a shared-bathroom room to £224 per week for a large ensuite, equivalent to £9,486–£11,424 for the contract. Prices may rise for 2027 entry. Against the current £21,805 UKRI minimum, lower-cost university housing would consume roughly 44% of the annual stipend before food, local travel, personal costs and savings.

That budget is plausible for a single student if tuition is fully covered, but it is not generous and should not be used to absorb an overseas-fee gap. Immigration and relocation costs also need separate planning unless the funding letter covers them.

Chinese Applicant Eligibility and Fit

Chinese nationality is not a published bar. The formal project criterion is at least a relevant UK 2:1-equivalent degree, usually in chemistry, chemical engineering or a closely related field. York's China country page says that a research degree normally requires a recognised bachelor's degree plus a relevant master's degree or research experience. The York Chemistry PhD page accepts international equivalents but warns that funded studentships are highly competitive and normally demand a profile stronger than the formal minimum.

Non-native English speakers must meet York's current subject-specific requirement. The university's 2027/28 PGR English page lists accepted tests, recency and exemption routes. Applicants should use the Chemistry requirement shown at submission time and retain formal evidence; they should not infer a required score from a different department.

A Chemistry PhD involving sensitive subject matter may also require an Academic Technology Approval Scheme certificate depending on nationality, course code and research description. The final offer and current York/UK guidance should determine this. Because the CDT includes activity at more than one university, the applicant should ensure that any required application accurately reflects the host and additional research location.

Strong-fit profile

The strongest applicant is likely to show:

• a sound foundation in inorganic, coordination, medicinal or synthetic chemistry;
• evidence of independent research reasoning rather than only taught laboratory competence;
• rigorous analytical interpretation and an understanding of confirmation and reproducibility;
• basic coding, quantitative analysis or structured data experience, with honest awareness of model limitations;
• willingness to learn microbiology and target biology without overstating current expertise;
• clear motivation for AMR, sustainability and responsible research;
• ability to communicate across disciplinary and institutional boundaries. Prior robot operation is an advantage, not necessarily a prerequisite. An applicant can compensate with evidence of reproducible workflow design, methodical troubleshooting and data discipline. Similarly, a chemistry applicant need not already be a microbiologist, but should show that they understand why target-level and whole-cell evidence answer different questions.

Profiles needing caution

• A purely computational applicant who wants little experimental chemistry may find the project misaligned.
• A purely microbiological applicant without strong chemistry evidence may struggle with the synthetic and analytical core.
• An applicant who needs a low-risk, linear PhD should be cautious: later translation is uncertain and cross-site coordination adds complexity.
• Anyone who cannot obtain written overseas-fee closure should not treat “international applicants welcome” as sufficient.

Ethics, Safety, Data and IP Governance

York's research-integrity code requires appropriate approvals before research, avoidance of harm, reliable record-keeping, clear data-management arrangements, secure access controls and conflict-of-interest management. These duties are directly relevant to P10 because the project spans potentially hazardous chemistry, biological materials, a commercial donor/partner context and ML-guided decisions.

The university's biological-safety guidance establishes a formal approval framework for specified biological hazards and genetically modified materials. P10's public description refers to later work involving clinically relevant and engineered bacterial materials, but it does not state which institution owns those approvals or where such work occurs. The applicant should verify that materials, containment, transfer and training are already planned and that the PhD student is not expected to build an unsupported safety pathway.

York's AI-in-research policy is directed partly at the use of AI tools rather than custom model development, but its principles remain useful: human accountability, transparency, accuracy and bias checking, approved systems, and protection of confidential data and intellectual property. For P10, this translates into versioned datasets, documented inclusion/exclusion decisions, audit trails, leakage controls, uncertainty reporting and clear human authority over model-guided choices.

The most important governance questions are:

• provenance, licence and access rules for all datasets;
• separation of training, validation and prospective evaluation data;
• ownership and maintainability of code and models;
• chemical and biological risk ownership across York and Oxford;
• metal waste and environmental controls;
• conflict-of-interest management and freedom to report negative results;
• partner publication review, IP assignment and thesis access;
• whether any resistant-organism work triggers additional biosafety, material-transfer or dual-use review.

High-Priority Questions Before Applying or Accepting

1. For a Chinese national awarded P10, will the funding letter state that the full international tuition fee and all annual increases are covered for all four years?
2. Is P10 competing within the limited UKRI international allocation, and is any separate fee-gap scholarship required?
3. What exact stipend applies to the 2027/28 cohort, and are visa, health surcharge, relocation and York–Oxford travel paid separately?
4. Who is the named IOI co-supervisor, and who provides routine target-biology and microbiology supervision?
5. Who provides routine ML, statistics and data-engineering supervision?
6. What automation, analytical and compute capacity is reserved for P10, including technical support and downtime contingency?
7. What IOI facilities, staff time, datasets and materials are committed, and how much time will the student spend in Oxford?
8. What are the staged decision points and fallback thesis outputs if target-level findings do not reproduce or translate into whole-cell activity?
9. How will model leakage, small-sample uncertainty, domain shift and prospective validation be handled?
10. Who owns the compounds, raw and curated data, code and models, and what confidentiality, publication-review or thesis-embargo rules apply?
11. Which institution holds responsibility for biological approvals, chemical risk, material transfer, metal waste and any dual-use review?
12. How will sustainability be measured across material use, consumables, analytical repetition, automation energy and waste?
13. Which York-host checklist controls the personal statement, project preferences, CV, transcript, references and equality-data form?
14. Does the final course require ATAS, and what current Chemistry English-language threshold applies to this applicant?

Overall decision

P10 is one of the stronger opportunities in this intake for a candidate who genuinely wants to combine experimental chemistry with automation and data-guided discovery. The project is recorded on the official programme page and is scientifically well matched to Frei’s recent work. Its main weaknesses are not lack of topic credibility but incomplete public detail around international fee closure, cross-site supervision, guaranteed platform access and governance.

For a Chinese applicant, the recommended decision is apply if the scientific fit is strong, but treat the offer as conditional on written funding and operational clarification. A fully satisfactory offer should cover all four years of overseas tuition, identify the day-to-day York and IOI supervisors, specify partner and platform access, and provide clear data, safety, IP and publication rules. Without those confirmations, the project remains attractive academically but financially or operationally uncertain.

Evidence and Sources

The saved recruitment page states that it was updated on 13 October; that source-reported update date does not establish current vacancy availability. The cited publications serve distinct roles as a field review, an ML study and an automation study. The available materials do not provide complete ordered bylines or enough paper-specific detail to assess full-text methods.

Official project, programme and funding

• Official P10 project description
• CSHP CDT home and 2027-entry status
• CSHP CDT application process
• CSHP international-funding FAQ
• University of York CSHP funding page
• UKRI support for funded students
• UKRI training-grant guidance
• York international postgraduate research fees

School, supervisor, partner and facilities

• York Chemistry department overview
• Angelo Frei official profile
• Angelo Frei institutional research record
• York Digital Chemistry theme
• York Green Chemistry facilities
• INEOS Oxford Institute founding
• Oxford AMR Network

Publications and field evidence

• Metals to combat antimicrobial resistance
• ML prediction of ruthenium-complex antibacterial activity
• High-throughput functional metal-complex discovery
• UK AMR action plan 2024–2029
• UK life-sciences skills assessment

Applicant, cost and governance

• York China country guidance
• York Chemistry PhD requirements
• York 2027/28 PGR English requirements
• York postgraduate accommodation
• York research-integrity code
• York biological-safety guidance
• York AI-in-research policy